Bank Of New York Mellon Corp Ocugen, Inc. Transaction History

Bank Of New York Mellon Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$1.11 - $1.87 $1.07 Million - $1.81 Million	967,759 New	967,759 $1.26 Million
Q3 2022 Nov 14, 2022	BUY	$1.75 - $3.1 $110,416 - $195,594	63,095 Added 7.04%	959,953 $1.71 Million
Q2 2022 Aug 15, 2022	BUY	$1.83 - $3.45 $260,416 - $490,948	142,304 Added 18.86%	896,858 $2.04 Million
Q1 2022 May 11, 2022	SELL	$2.34 - $4.72 $70,897 - $143,006	-30,298 Reduced 3.86%	754,554 $2.49 Million
Q4 2021 Feb 11, 2022	BUY	$4.38 - $15.67 $93,079 - $333,003	21,251 Added 2.78%	784,852 $3.57 Million
Q3 2021 Nov 12, 2021	BUY	$6.36 - $8.51 $433,624 - $580,211	68,180 Added 9.8%	763,601 $5.48 Million
Q2 2021 Aug 11, 2021	BUY	$5.52 - $15.68 $3.35 Million - $9.52 Million	607,207 Added 688.33%	695,421 $5.58 Million
Q1 2021 May 13, 2021	SELL	$1.66 - $15.81 $32,542 - $309,939	-19,604 Reduced 18.18%	88,214 $598,000
Q4 2020 Feb 09, 2021	BUY	$0.28 - $2.6 $30,189 - $280,326	107,818 New	107,818 $197,000

124

78.3M

535K

523K

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $175M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.